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Abstract
Summary In a phase 2 trial of 222 postmenopausal women
with osteoporosis aged 55 to 85 years randomized to one
of three different doses of abaloparatide-SC, subcutaneous
teriparatide, or placebo for 24 weeks, abaloparatide-SC
resulted in improvements in skeletal microarchitecture as
measured by the trabecular bone score.
Introduction Subcutaneous abaloparatide (abaloparatide-
SC) increases total hip and lumbar spine bone mineral den-
sity and reduces vertebral and non-vertebral fractures. In
this study, we analyzed the extent to which abaloparatide-
SC improves skeletal microarchitecture, assessed indirect-
ly by trabecular bone score (TBS).
Methods This is a post hoc analysis of a phase 2 trial of 222
postmenopausal women with osteoporosis aged 55 to 85 years
randomized to abaloparatide-SC (20, 40, or 80 μg), subcuta-
neous teriparatide (20 μg), or placebo for 24 weeks. TBS was
measured from lumbar spine dual X-ray absorptiometry
(DXA) images in 138 women for whom the DXA device
was TBS software compatible. Assessments were made at
baseline, 12 and 24 weeks. Between-group differences were
assessed by generalized estimating equations adjusted for rel-
evant baseline characteristics, and a pre-determined least sig-
nificant change analysis was performed.
Results After 24 weeks, TBS increased significantly by 2.27,
3.14, and 4.21% versus baseline in participants on 20, 40, and
80 μg abaloparatide-SC daily, respectively, and by 2.21% in
those on teriparatide (p < 0.05 for each). The TBS in the pla-
cebo group declined by 1.08%. The TBS increase in each
treatment group was significantly higher than placebo at
24 weeks (p < 0.0001 for each) after adjustment for age,
BMI, and baseline TBS. A dose-response was observed at
24 weeks across the three doses of abaloparatide-SC and pla-
cebo (p = 0.02). The increase in TBS in the abaloparatide-SC
80 μg group was significantly greater than TPTD (p < 0.03).
Conclusions These results are consistent with an effect of
abaloparatide-SC to improve lumbar spine skeletal
microarchitecture, as assessed by TBS.
Keywords Anabolics . Bonemicroarchitecture . Clinical
trials . Osteoporosis
Introduction
Abaloparatide, a novel 34-amino acid peptide designed to be a
selective activator of the PTH1 receptor signaling pathway, is a
promising therapeutic approach to the treatment of osteoporo-
sis. Abaloparatide binds selectively to the RG versus R0 con-
formation of the PTH1 receptor, resulting in transient receptor
signaling consistent with a net anabolic effect [1]. The results of
the phase 3 ACTIVE trial of abaloparatide for subcutaneous
injection (abaloparatide-SC) demonstrated efficacy in reducing
vertebral and non-vertebral fracture incidence [2].
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Abaloparatide-SC improves trabecular microarchitecture
as assessed by trabecular bone score (TBS): a 24-week
randomized clinical trial
We hypothesized that since abaloparatide-SC is an activa-
tor of the PTH1 receptor, it is likely that its efficacy is related
to improved bone microarchitecture and strength, as has been
shown for teriparatide [3, 4]. To this point, animal studies with
abaloparatide-SC have documented complete reversal of bone
loss in ovariectomy-induced osteopenic rats and monkeys [1,
5, 6]. In monkeys, abaloparatide-SC augments not only bone
mass and volume, but also bone microarchitecture and bone
strength [7]. In both animal models, the increased bone for-
mation occurs in the absence of a corresponding increase in
bone resorption, resulting in marked gains in bone mass and
strength [7, 8]. To date, however, the effects of abaloparatide-
SC on trabecular microarchitecture and bone strength have not
been assessed in human subjects.
The trabecular bone score (TBS) is a non-invasive imaging
technology that takes advantage of the DXA lumbar spine
image, providing skeletal information not captured by stan-
dard bone mineral density (BMD) assessments. It is a gray-
level textural analysis that utilizes experimental variograms to
assess 2D projection images from the DXA scan [9]. A semi-
quantitative measurement, TBS is strongly correlated with a
number of microarchitectural parameters that reflect bone
strength [10]. A high TBS reflects better microarchitecture;
whereas, a low TBS reflects worse microarchitecture [11]. In
a recent meta-analysis, TBS was demonstrated to be a signif-
icant predictor of fracture risk independent of Fracture Risk
Assessment Tool (FRAX)-calculated 10-year fracture risk es-
timate [12].
The primary objective of this study was to utilize TBS in a
six-month clinical trial of several different doses of
abaloparatide-SC, a single dose of teriparatide, or placebo
[13], to determine the extent to which abaloparatide-SC im-
proves skeletal microarchitecture.
Methods
This study is a post hoc retrospective analysis of a phase 2,
multicenter, international, and double-blind placebo-con-
trolled trial conducted at 30 study centers across four coun-
tries: the USA, Argentina, India, and the UK [13]. All
patients had provided informed written consent prior to
their participation, in accordance with the Declaration of
Helsinki for research on human subjects.
To be eligible for inclusion in the original trial, patients had
to be postmenopausalwomenwith osteoporosis, aged 55 years
old or older, and not currently on long-term treatment for
osteoporosis. In addition, patients could not currently be on
systemic corticosteroids and could not have any other bone or
spinal disease or history of past injuries or surgeries (e.g., total
hip replacement, spinal rods) that would alter BMD measure-
ments at the lumbar spine or hip. Once screened and con-
firmed for eligibility, patients were randomized to one of the
following five treatment arms, with each patient self-
administering a single subcutaneous injection once daily for
24 weeks of placebo; one of three different doses of
abaloparatide-SC (20, 40, or 80 μg); and teriparatide 20 μg.
All patients also received supplemental calcium (500 to
1000 mg) and vitamin D (400 to 800 IU), in accordance with
local practices. Patients and investigators remained blinded to
treatment with all doses of abaloparatide-SC and placebo
throughout the study. Blinding was not possible in patients
randomized to receive teriparatide because the drug could be
delivered only via its trademarked injection pen [13].
BMD was assessed in the lumbar spine, femoral neck,
and total hip by DXA at baseline and again at 12 and
24 weeks after the initiation of treatment. DXA scans were
sent to a central imaging reader (BioClinica Inc.,
Doylestown, PA, USA) for a quality control review,
followed by analysis in accordance with each manufac-
turer’s instructions and ISCD guidelines. The two follow-
up scans on each given patient were performed on the same
instrument used at baseline. Each study site performed in-
strument quality control assessments over time (i.e., instru-
ment standardization and phantom calibration), which
were reviewed by the central reader. Further details on
the methodology of the original trial have been published
[13]. All vertebrae (L1 to L4) were automatically included
into the analysis (about 84% of all patients). However,
individual vertebrae were excluded if fractures or degener-
ative changes were present, in accordance with ISCD rules
for individual vertebrae exclusion (more than 1 standard
deviation in T-score from the immediately adjacent
vertebrae).
To be eligible for the current study, patients had to
have had their initial BMD measurement on a DXA scan-
ner compatible with TBS software. TBS was calculated
retrospectively using a modified TBS Calculator (v2.2)
to consider soft tissue thickness directly in the algorithm
instead of BMI (Medimaps group, Plan-les-Ouates,
Geneva, Switzerland), using DXA files from the original
phase 2 trial. All patient identifiers were removed to
maintain anonymity and to ensure blinding of the investi-
gators to all clinical parameters and outcomes. The same
region of interest as BMD was used with vertebral site
exclusions as noted above. Of 222 women randomized
to one of the five treatment arms, 221 received at least
one dose of study medication. TBS could not be calculat-
ed in 76 patients because the DXA scanner or the acqui-
sition mode used was incompatible with TBS software.
Additional patients (n = 4) were excluded as a DXA
change in software (upgrade to convert a QDR 4500 W
to a Discovery W) was performed in the middle of the
study without TBS cross-calibration, or the DXA
displayed malfunctioning detectors (n = 3) that could have
led to errors in the TBS calculations.
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Statistical analysis
The primary outcome of interest was the change in TBS in the
lumbar spine relative to baseline, assessed both by percentage
change from baseline and by generalized estimating equations
(GEE), adjusted for TBS, BMI, and age at baseline; treatment,
visit, and treatment and visit interaction; and an unstructured
covariance structure. A dose-response curve was calculated
for the placebo group and 20, 40, or 80 μg dose groups of
abaloparatide-SC. At 24 weeks, the percentage of individuals
exceeding two different levels of a priori-determined least
significant change (LSC) was calculated for each group,
where LSC was defined as the extent of change above which
a difference in TBS could be presumed real and not secondary
to precision errors. The differences in proportion of patients
with an increase ≥ LSC were tested using the chi-square cat-
egorical test. The published precision errors for TBS vary
from 1.12 to 2.1% depending on the design of the study and
machine involved. The average precision across these studies
was approximatively 1.53% and the corresponding LSC at
95% confidence interval was ± 4.2% [3, 11, 14, 15]. This latter
value was used in this study. All inferential testing was two-
tailed, with p ≤ 0.05 set as the threshold for statistical signifi-
cance. IBM SPSS statistical software (version 21.0; SPSS,
Inc.) was used for all statistics.
Results
The 138 patients included in the final analysis were generally
similar to the original study population with respect to age,
BMI, and lumbar spine BMD at baseline. Patients in the five
treatment groups were also similar in their demographic and
clinical characteristics, including baseline lumbar spine BMD
and TBS measurements (Table 1).
Figure 1 shows the change in TBS over time in patients on
placebo, teriparatide, and the three different doses of
abaloparatide-SC. Results are expressed as percentage change
(mean ± standard error of the mean) from baseline at 12 and
24 weeks in lumbar spine TBS. After 12 weeks, lumbar spine
TBS increased by 1.33, 1.86, 2.37, and 1.16% in the
abaloparatide-SC 20 μg, abaloparatide-SC 40 μg,
abaloparatide-SC 80 μg, and teriparatide groups, respectively
(p < 0.05 for all comparisons to baseline); whereas, there was
no significant increase in the placebo group (+ 0.23%, p =
0.35). After 24 weeks, TBS increased versus baseline by
2.27, 3.14, 4.21, and 2.21% in the abaloparatide-SC 20 μg,
abaloparatide-SC 40 μg, abaloparatide-SC 80 μg, and
teriparatide groups, respectively (p < 0.05 for all comparisons
to baseline); while, there was a non-significant decrease in the
placebo group (− 1.08%, p = 0.13).
GEE analysis, adjusted for treatment group, visit, treatment
group and visit interaction, TBS at baseline, age at baseline,
and BMI at baseline, showed that TBS at 12 weeks increased
significantly versus placebo in patients in the abaloparatide-
SC 40 μg (1.61%, p = 0.03) and 80 μg (2.07%, p = 0.02)
groups, but not in the abaloparatide-SC 20 μg (1.10%, p =
0.15) or teriparatide (1.00%, p = 0.21) groups. No significant
differences were observed between teriparatide and the
abaloparatide-SC 20 μg (0.08%, p = 0.91), abaloparatide-SC
40 μg (0.59%, p = 0.42) or abaloparatide-SC 80 μg (1.02%,
p = 0.24) groups.
At 24 weeks, all treated groups displayed significant TBS
improvements versus placebo. TBS increased by 3.25%
(p < 0.001) in the abaloparatide-SC 20 μg group, 4.17%
(p < 0.001) in the abaloparatide-SC 40 μg group, 5.23%
(p < 0.001) in the abaloparatide-SC 80 μg group, and 3.27%
(p = 0.002) in the teriparatide group. TBS also increased sig-
nificantly more in patients treated with abaloparatide-SC
80 μg (1.90%, p = 0.04), but not in those treated with
abaloparatide-SC 20 μg (0.06%, p = 0.95) or abaloparatide-
SC 40 μg (0.86%, p = 0.40) groups compared to those treated
with teriparatide. Additionally, a positive dose-response was
observed at 24 weeks (least square regression ± standard error
= 0.03 ± 0.01; p = 0.02) when comparing the three different
doses of abaloparatide-SC and placebo.
Table 1 Baseline characteristics
of the five treatment groups
expressed as mean ± SD. No
significant differences were found
among groups for each reported
parameter
N = 138 ABL-SC
80 μg n = 24
ABL-SC
40 μg n = 25
ABL-SC
20 μg n = 29
TPTD
n = 31
Placebo
n = 29
Mean SD Mean SD Mean SD Mean SD Mean SD
Age (years) 64.3 6.9 65.4 6.9 68.1 6.3 66.2 7.3 66.7 7.6
BMI
(kg/m2)
25.6 3.4 26.1 3.9 26.4 2.7 26.7 3.1 25.5 3.3
Lumbar spine
BMD
(g/cm2)
0.765 0.111 0.752 0.080 0.767 0.103 0.762 0.096 0.796 0.102
Lumbar spine
TBS
1.181 0.078 1.188 0.762 1.189 0.063 1.201 0.068 1.196 0.067
ABL-SC abaloparatide-SC, BMD bone mineral density, BMI body mass index, TBS trabecular bone score, TPTD
teriparatide
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On LSC analysis (Table 2), the percentages of patients on
80 μg abaloparatide-SC daily, teriparatide 20 μg, and placebo
who experienced greater than a 4.2% increase in TBS versus
baseline were 52.2, 30.0, and 10.2%, respectively. No statis-
tical difference was found between the abaloparatide-SC
80 μg and teriparatide groups (p = 0.12) but the 80 μg
abaloparatide-SC group displayed a statistically significant
difference versus placebo (p < 0.01). Differences between
the teriparatide and placebo groups were not statistically sig-
nificant (p = 0.06). None of the patients in the abaloparatide-
SC 80 μg group experienced a decrease in TBS versus base-
line greater than the LSC, versus 6.7% of patients in the
teriparatide group.
For both the teriparatide and abaloparatide-SC 80 μg
groups, we calculated the number of patients exceeding the
LSC for lumbar spine BMD using the same 4.2% threshold as
for TBS. In the abaloparatide-SC 80 μg group, 52 and 74% of
patients exceeded the LSC for the lumbar spine TBS and
BMD, respectively, and 35% of patients exceeded the LSC
in both parameters. Results are 30 and 60% for teriparatide
patients for lumbar spine TBS and BMD, respectively, and
27% for both parameters.
Discussion
Adding to the insights gained from the previously pub-
lished BMD results in the same phase 2 study population
[13], this analysis of the effect of abaloparatide-SC shows
significant enhancement of TBS relative to placebo.
Similar TBS results with teriparatide have been observed
but over a longer period of time (18 to 24 months
Fig. 1 Comparing change in the trabecular bone score over time in
patients on placebo, teriparatide, and three different doses of
abaloparatide-SC (20, 40, and 80 μg). Results are expressed in
percentage change (mean ± SEM) from baseline at 12 and 24 weeks in
lumbar spine TBS. TBS increases from baseline were significant for
teriparatide and for all three doses of abaloparatide-SC, at 12 and
24 weeks (p < 0.05 for all comparisons to baseline). For placebo, there
was no significant increase at 12 weeks (p = 0.35) and a non-significant
decrease at 24 weeks (p = 0.13)
Table 2 Least significant change
(LSC) analysis comparing
abaloparatide-SC 80 μg,
teriparatide (TPTD), and placebo
for two different LSC levels
At 6 months
LSC 95% ABL-SC 80 μg TPTD Placebo
Significant individual gain (%) + 4.20 52.2* 30.0‡ 10.3
Significant individual loss (%) − 4.20 0.0¥ 6.7 17.2
ABL-SC abaloparatide-SC, LSC least significant change, TPTD teriparatide
*p = 0.001 versus placebo
‡ p = 0.06 versus placebo
¥ p = 0.05 versus placebo
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compared to 6 months here) [3]. Moreover, at both 12 and
24 weeks, the magnitude by which TBS increased was
greater in the 80-μg dose group of abaloparatide-SC (the
dose that was used in the subsequent larger phase 3 trial)
than in the teriparatide group. Similar results were ob-
served for the 40-μg abaloparatide-SC cohort. On aver-
age, in the different treatment groups, less than 10% of
the variations of the BMD were explained by the varia-
tions of TBS, confirming that both parameters are unre-
lated, at least in part, and represent different bone proper-
ties. Also of note, an increase in TBS greater than the
LSC (4.2%) was achieved by 52.2% of patients treated
with abaloparatide-SC 80 μg versus 30.0% of those treat-
ed with teriparatide. The percentage of patients on place-
bo exhibiting a 4.2% increase over baseline was 10.3%. It
is also interesting to note that 35% of the patients treated
with 80 μg of abaloparatide increased significantly (ex-
ceeding their LSC) both their lumbar spine BMD and
TBS compared to 27% for patients treated with
teriparatide.
Several relatively small studies have investigated the effect
of bone-active substances on TBS [16] and suggested that
TBS tends to increase with treatments that increase lumbar
spine BMD and to decrease without treatment. The response
usually parallels the changes observed on BMD but to a lesser
extent for TBS. In contrast, the magnitude of the decrease in
TBS without treatment is very similar to that of BMD. It is
interesting to note that there is a different TBS response de-
pending upon the type of treatment [16]. Usually, the anti-
resorptive drugs preserve bone structure, an effect supported
by the mechanism of action of these agents. In these instances,
monitoring TBS changes do not add substantially to what
would be observed by monitoring BMD alone. However, a
safety issue is relevant if TBS values were to decline signifi-
cantly over time, causing concern perhaps for increased risk of
fracture. In contrast, exposure to anabolic treatment is associ-
ated with an increase in TBS values above the LSC in almost
two thirds of patients undergoing treatment [3]. In addition,
with TBS monitoring, only 10% of patients demonstrated a
decline in TBS values. In this latter case, monitoring TBS
could also have clinical relevance. Whether the increase in
TBS values in the context of anabolic treatment is associated
with a reduction in fracture risk, over and above what an
increase in BMD would indicate, remains yet to be
demonstrated.
Limitations of this study include the lack of blinding of the
teriparatide group. However, the TBS analysis is an objective
measure and was carried out in blinded fashion without regard
to the experimental arm of the study. Another limitation of this
study is that it is a post hoc analysis of a phase 2 trial. The
exclusion of 76 patients from the original study population is
an additional limitation. However, the subgroup of analyzed
patients was generally similar to the original study population
with respect to several key baseline characteristics (age, BMI,
and lumbar spine BMD at baseline). The patient sample also
excluded women under age 55, men of any age, and patients
with secondary sources of osteoporosis, such as chronic glu-
cocorticoid steroid use, so the results presented here cannot be
extrapolated beyond the current study population.
These results help to differentiate further abaloparatide-SC
from teriparatide in terms of potential effects on skeletal
microarchitecture as determined indirectly by TBS, and pro-
vide additional support for the development of abaloparatide-
SC as a new anabolic treatment for postmenopausal
osteoporosis.
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